Paper
Postmarketing Surveillance Study of OxyContin® Tablets for Relieving Moderate to Severe Postherpetic Neuralgia Pain
Published Aug 1, 2008 · B. Fan
Oncology
9
Citations
0
Influential Citations
Abstract
Objective: To evaluatethe efficacy and safety of OxyContin®tablets(controlled-release oxycodone hydrochloride: 5, 10, 20, and 40 mg) in relieving moderate to severe postherpetic neuralgia (PHN) pain. Method: A multicenter, open-label, prospective, self-controlled clinical observation. Results: Pain was relieved in 17.3% of patients within 30 min and in 94.1% patients within 1 h after drug administration. OxyContin® tablets showed good clinical efficacy in relieving both moderate and severe PHN pain. Response rate reached 98.4% at the end of the 8th week of treatment. After the 1st week of treatment, stable pain relief was achieved, and pain scores on a Visual Analogue Scale decreased dramatically in most patients. During treatment with controlled-release OxyContin® tablets, the use of concomitant medications was significantly decreased. Some patients developed adverse drug reactions (ADRs) in the 1st week, which decreased significantly during the following weeks of treatment. Nausea (18.1%) was the most commonly reported ADR, followed by constipation (10.1%) and dizziness (10.1%). A number of ADRs disappeared during treatment. Conclusion: Controlled-release OxyContin® tablets demonstrated fast onset of PHN pain control, superior efficacy in relieving both moderate and severe PHN pain, and a good safety profile.
Non-RCTOxyContin® tablets provide fast onset of postherpetic neuralgia pain relief, with good safety profile and effective relief of both moderate and severe pain.
Full text analysis coming soon...